Patents by Inventor Amriti R. Lulla

Amriti R. Lulla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of tumors with miRNA targeting CDK4/CDK6
    Patent number: 11859183
    Abstract: The present disclosure provides miRNA mimics targeting CDK4 and/or CDK6, and compositions comprising the same. Methods for the treatment of tumors, including but not limited to colon cancer, comprising administering a modified oligonucleotide comprising a miRNA are also disclosed herein.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: January 2, 2024
    Assignee: Institute For Cancer Research
    Inventors: Amriti R. Lulla, Wafik S. El-Deiry
  • MIR-3132 UPREGULATION OF THE TRAIL PATHWAY AND APOPTOTIC ACTIVITY IN CANCER CELLS
    Publication number: 20230340478
    Abstract: The present disclosure provides compositions comprising miR-3132 and one or more pharmaceutical agents that upregulate TNF-related apoptosis-inducing ligand (TRAIL) or activate TRAIL signaling pathway, and methods for treating a cancer comprising administering miR-3132, or a composition comprising miR-3132 and one or more pharmaceutical agents that upregulate TRAIL or activate TRAIL signaling pathway, to a subject.
    Type: Application
    Filed: January 4, 2023
    Publication date: October 26, 2023
    Inventors: Amriti R. Lulla, Wafik S. El-Deiry
  • miR-3132 upregulation of the TRAIL pathway and apoptotic activity in cancer cells
    Patent number: 11578324
    Abstract: The present disclosure provides compositions comprising miR-3132 and one or more pharmaceutical agents that upregulate TNF-related apoptosis-inducing ligand (TRAIL) or activate TRAIL signaling pathway, and methods for treating a cancer comprising administering miR-3132, or a composition comprising miR-3132 and one or more pharmaceutical agents that upregulate TRAIL or activate TRAIL signaling pathway, to a subject.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: February 14, 2023
    Assignee: Institute For Cancer Research
    Inventors: Amriti R. Lulla, Wafik S. El-Deiry
  • MIR-3132 UPREGULATION OF THE TRAIL PATHWAY AND APOPTOTIC ACTIVITY IN CANCER CELLS
    Publication number: 20220098580
    Abstract: The present disclosure provides compositions comprising miR-3132 and one or more pharmaceutical agents that upregulate TNF-related apoptosis-inducing ligand (TRAIL) or activate TRAIL signaling pathway, and methods for treating a cancer comprising administering miR-3132, or a composition comprising miR-3132 and one or more pharmaceutical agents that upregulate TRAIL or activate TRAIL signaling pathway, to a subject.
    Type: Application
    Filed: March 11, 2019
    Publication date: March 31, 2022
    Inventors: Amriti R. Lulla, Wafik S. El-Deiry
  • TREATMENT OF TUMORS WITH MIRNA TARGETING CDK4/CDK6
    Publication number: 20220056452
    Abstract: The present disclosure provides miRNA mimics targeting CDK4 and/or CDK6, and compositions comprising the same. Methods for the treatment of tumors, including but not limited to colon cancer, comprising administering a modified oligonucleotide comprising a miRNA are also disclosed herein.
    Type: Application
    Filed: May 10, 2021
    Publication date: February 24, 2022
    Inventors: Amriti R. Lulla, Wafik S. El-Deiry
  • MIR-3132 UPREGULATION OF THE TRAIL PATHWAY AND APOPTOTIC ACTIVITY IN CANCER CELLS
    Publication number: 20210254060
    Abstract: The present disclosure provides compositions comprising miR-3132 and one or more pharmaceutical agents that upregulate TNF-related apoptosis-inducing ligand (TRAIL) or activate TRAIL signaling pathway, and methods for treating a cancer comprising administering miR-3132, or a composition comprising miR-3132 and one or more pharmaceutical agents that upregulate TRAIL or activate TRAIL signaling pathway, to a subject.
    Type: Application
    Filed: March 11, 2019
    Publication date: August 19, 2021
    Inventors: Amriti R. Lulla, Wafik S. El-Deiry
  • Treatment of tumors with miRNA targeting CDK4/CDK6
    Patent number: 11034959
    Abstract: The present disclosure provides miRNA mimics targeting CDK4 and/or CDK6, and compositions comprising the same. Methods for the treatment of tumors, including but not limited to colon cancer, comprising administering a modified oligonucleotide comprising a miRNA are also disclosed herein.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: June 15, 2021
    Assignee: Institute For Cancer Research
    Inventors: Amriti R. Lulla, Wafik S. El-Deiry
  • TREATMENT OF TUMORS WITH MIRNA TARGETING CDK4/CDK6
    Publication number: 20200056184
    Abstract: The present disclosure provides miRNA mimics targeting CDK4 and/or CDK6, and compositions comprising the same. Methods for the treatment of tumors, including but not limited to colon cancer, comprising administering a modified oligonucleotide comprising a miRNA are also disclosed herein.
    Type: Application
    Filed: February 26, 2018
    Publication date: February 20, 2020
    Inventors: Amriti R. Lulla, Wafik S. El-Deiry